Prior or current invasive malignancy with current evidence of active disease within the past 3 years
Other invasive malignancy within 2 years.
Prior breast cancer or other invasive malignancy treated within 5 years
Prior invasive malignancy of other histology currently requiring treatment
Prior breast cancer or other invasive malignancy treated within 5 years
For part B and part C, Presence of other active invasive cancers other than NSCLC or history of treatment for invasive cancer other than NSCLC in the past 3 years. Exceptions are:
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients with a history of another invasive malignancy within the last 3 years
COHORT 3: ENDOMETRIAL CANCER: Patients with a history of another invasive malignancy within the last 3 years
Prior therapy for glioblastoma or other invasive malignancy
Other invasive cancers diagnosed < 3 years back that required systemic treatment; if diagnosed with other invasive cancer >= 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia
Evidence of other active invasive malignancy requiring treatment other than surgery in the past 3 years
Prior history of invasive malignancy within the last 2 years
Concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years
EXCLUSION CRITERIA FOR REGISTRATION: concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years
Other active invasive malignancy; history of non-invasive malignancies such as ductal carcinoma in situ of the breast, non-melanomatous carcinoma of the skin, is allowed, as is history of other invasive malignancy that is in remission for >/= 5 years after treatment with curative intent
Uncontrolled prior invasive malignancy, excluding the current diagnosis
Patient has been diagnosed and/or treated for any invasive cancer (other than study disease) less than 5 years prior to study enrollment.
Subjects with a history of another invasive malignancy ?3 years of study drug initiation.
Other invasive malignancy within the past 3 years.
History of another invasive cancer within 3 years of randomization;
Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years of study start
History of a prior invasive malignancy in past 5 years
Evidence of other active, invasive malignancy requiring treatment within the past 5 years; noninvasive cancer history (such as carcinoma-in-situ [CIS] that has been resected) is allowed
Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment
Patients with a history within the last 3 years of another invasive malignancy.
Other invasive malignancy within 2 years
Other invasive malignancy within 2 years
Invasive or active malignancy in past 2 years
No invasive tumors within the last 5 years unless confined to an organ (e.g. prostate or thyroid cancer) and treated with curative therapy (e.g. surgery and/or radiation); please note, there must be no evidence of the prior malignancy using standard criteria to evaluate the specific prior malignancy
Prior invasive malignancy of other histology currently requiring treatment
Invasive malignancy or history of invasive malignancy other than disease under study: any other invasive malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigator and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on currently targeted malignancy, can be included in this clinical trial; Curatively treated non-melanoma skin cancer and any carcinoma-in-situ.
Patients with prior invasive malignancy within two years of enrollment are excluded
Invasive malignancy or history of invasive malignancy other than disease under study within the last two years except: Any other invasive malignancy for which the subject was definitively treated, has been disease-free for <=2 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial; and curatively treated non-melanoma skin cancer.
Any prior invasive malignancy within 5 years before randomization
Any non-invasive malignancy not treated with curative intent or with knownactive disease within 5 years before randomization
Subjects must not have another active invasive malignancy, with the following exceptions and notes: